tradingkey.logo
搜索

Myriad Genetics Inc

MYGN
添加自选
3.884USD
-0.186-4.56%
交易中 美东报价延迟15分钟
366.68M总市值
亏损市盈率 TTM

Myriad Genetics Inc

3.884
-0.186-4.56%
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-4.56%

5天

-22.78%

1月

-10.71%

6月

-40.61%

今年开始到现在

-36.84%

1年

-8.60%

TradingKey Myriad Genetics Inc股票评分

单位: USD 更新时间: 2026-05-12

操作建议

Myriad Genetics Inc当前公司基本面数据相对非常健康,最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理,在医疗设备与耗材行业排名86/206位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价6.22。中期看,股价处于平稳状态。近一个月,市场表现非常差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Myriad Genetics Inc评分

相关信息

行业排名
86 / 206
全市场排名
203 / 4490
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Myriad Genetics Inc亮点

亮点风险
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
利润高增长
公司净利润处于行业前列,最新年度总收入824.50M美元
估值高估
公司最新PE估值-0.94,处于3年历史高位
机构减仓
最新机构持股102.95M股,环比减少6.61%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓,最新持仓市值2.33K
活跃度降低
近期活跃度降低,过去20天平均换手率0.10

分析师目标

根据 11 位分析师
持有
评级
6.222
目标均价
+45.04%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Myriad Genetics Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Myriad Genetics Inc简介

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
公司代码MYGN
公司Myriad Genetics Inc
CEORaha (Samraat S)
网址https://myriad.com/
KeyAI